149 related articles for article (PubMed ID: 8771239)
1. The role of the renin-angiotensin system in cisplatin nephrotoxicity.
Deegan PM; Nolan C; Ryan MP; Basinger MA; Jones MM; Hande KR
Ren Fail; 1995 Nov; 17(6):665-74. PubMed ID: 8771239
[TBL] [Abstract][Full Text] [Related]
2. Blockade by intravenous losartan of AT1 angiotensin II receptors in rat brain, kidney and adrenals demonstrated by in vitro autoradiography.
Zhuo J; Song K; Abdelrahman A; Mendelsohn FA
Clin Exp Pharmacol Physiol; 1994 Jul; 21(7):557-67. PubMed ID: 7982288
[TBL] [Abstract][Full Text] [Related]
3. Effect of losartan and enalapril on renal adaptation sodium restriction in rat.
Jover B; Saladini D; Nafrialdi N; Dupont M; Mimran A
Am J Physiol; 1994 Aug; 267(2 Pt 2):F281-8. PubMed ID: 8067389
[TBL] [Abstract][Full Text] [Related]
4. The selective angiotensin AT1 receptor antagonist LR-B/081 potently inhibits drinking induced by central injection of angiotensin II in rats.
Polidori C; Ciccocioppo R; Pompei P; Cirillo R; Massi M
Eur J Pharmacol; 1995 Apr; 277(2-3):223-8. PubMed ID: 7493612
[TBL] [Abstract][Full Text] [Related]
5. Acute and chronic losartan administration: effect on angiotensin II content and modulation of [3H]norepinephrine release from rat interscapular brown adipose tissue.
Cassis LA; Dwoskin LP
J Neural Transm Gen Sect; 1994; 98(2):159-64. PubMed ID: 7734113
[TBL] [Abstract][Full Text] [Related]
6. Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects.
Gorbea-Oppliger VJ; Melaragno MG; Potter GS; Petit RL; Fink GD
J Pharmacol Exp Ther; 1994 Nov; 271(2):804-10. PubMed ID: 7965799
[TBL] [Abstract][Full Text] [Related]
7. Intravenous losartan inhibits the increase in plasma luteinizing hormone and water intake produced by intraventricular angiotensin II.
Palmer AA; Steele MK; Shackelford RL; Ganong WF
Proc Soc Exp Biol Med; 1994 Mar; 205(3):263-6. PubMed ID: 8171048
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist.
Cassis LA; Rippetoe PE; Soltis EE; Painter DJ; Fitz R; Gillespie MN
J Pharmacol Exp Ther; 1992 Sep; 262(3):1168-72. PubMed ID: 1527721
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats.
von Lutterotti N; Camargo MJ; Campbell WG; Mueller FB; Timmermans PB; Sealey JE; Laragh JH
J Hypertens; 1992 Sep; 10(9):949-57. PubMed ID: 1328376
[TBL] [Abstract][Full Text] [Related]
10. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats.
Keith DS; Torres VE; Johnson CM; Holley KE
Am J Kidney Dis; 1994 Sep; 24(3):491-8. PubMed ID: 8079975
[TBL] [Abstract][Full Text] [Related]
11. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems.
Burnier M; Pechère-Bertschi A; Nussberger J; Waeber B; Brunner HR
Am J Kidney Dis; 1995 Jul; 26(1):108-15. PubMed ID: 7611241
[TBL] [Abstract][Full Text] [Related]
12. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril.
Burdmann EA; Andoh TF; Nast CC; Evan A; Connors BA; Coffman TM; Lindsley J; Bennett WM
Am J Physiol; 1995 Oct; 269(4 Pt 2):F491-9. PubMed ID: 7485533
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin system and minoxidil-induced cardiac hypertrophy in rats.
Ruzicka M; Leenen FH
Am J Physiol; 1993 Nov; 265(5 Pt 2):H1551-6. PubMed ID: 8238566
[TBL] [Abstract][Full Text] [Related]
14. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist.
Bertolino F; Valentin JP; Maffre M; Jover B; Bessac AM; John GW
J Pharmacol Exp Ther; 1994 Feb; 268(2):747-52. PubMed ID: 8113986
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats.
Kohzuki M; Yasujima M; Kanazawa M; Yoshida K; Fu LP; Obara K; Saito T; Abe K
J Hypertens; 1995 Jan; 13(1):97-103. PubMed ID: 7759858
[TBL] [Abstract][Full Text] [Related]
16. Chronic Losartan treatment blocks isoproterenol-induced dipsogenesis.
Iyer SN; Wright BE; Strubbe G; Hanley K; Katovich MJ
Physiol Behav; 1995 Aug; 58(2):283-6. PubMed ID: 7568431
[TBL] [Abstract][Full Text] [Related]
17. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
Siegl PK; Chang RS; Mantlo NB; Chakravarty PK; Ondeyka DL; Greenlee WJ; Patchett AA; Sweet CS; Lotti VJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):139-44. PubMed ID: 1625193
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass.
Pollock DM; Divish BJ; Polakowski JS; Opgenorth TJ
J Pharmacol Exp Ther; 1993 Nov; 267(2):657-63. PubMed ID: 8246138
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.
Lafayette RA; Mayer G; Park SK; Meyer TW
J Clin Invest; 1992 Sep; 90(3):766-71. PubMed ID: 1522231
[TBL] [Abstract][Full Text] [Related]
20. Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists.
Owen RA; Molon-Noblot S; Hubert MF; Siegl PK; Eydelloth RS; Keenan KP
Lab Invest; 1994 Oct; 71(4):543-51. PubMed ID: 7967510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
